Atorvastatin induces T cell proliferation by a telomerase reverse transcriptase (TERT) mediated mechanism

Atherosclerosis

Volumn 236, Issue 2, 2014, Pages 312-320

  Bennaceur, Karim ^a   Atwill, Mark ^a   Al Zhrany, Nayef ^a   Hoffmann, Jedrzej ^a   Keavney, Bernard ^a   Breault, David ^b   Richardson, Gavin ^a   von Zglinicki, Thomas ^a   Saretzki, Gabriele ^a   Spyridopoulos, Ioakim ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

Atorvastatin; Human; Mouse; T lymphocytes; Telomerase; TERT

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; TERT PROTEIN, HUMAN; TERT PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CELL MATURATION; CHOLESTEROL METABOLISM; CONTROLLED STUDY; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE; TURNOVER TIME; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARDIOVASCULAR DISEASES; CELL CULTURE; CELL DIVISION; DOSE RESPONSE; DRUG EFFECTS; ENZYME INDUCTION; ENZYMOLOGY; GENETICS; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; REPORTER GENE; RISK; TELOMERE; TELOMERE HOMEOSTASIS; TRANSGENIC MOUSE; ULTRASTRUCTURE;

ANIMALS; ATORVASTATIN CALCIUM; CARDIOVASCULAR DISEASES; CATALYTIC DOMAIN; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELLS, CULTURED; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; GENES, REPORTER; HEPTANOIC ACIDS; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PYRROLES; RISK; TELOMERASE; TELOMERE; TELOMERE HOMEOSTASIS;

EID: 84907079903     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.07.020     Document Type: Article

References (43)

1. Vega L.R., Mateyak M.K., Zakian V.A. Getting to the end: telomerase access in yeast and humans. Nat Rev Mol Cell Biol 2003, 4(12):948-959.
2. Blasco M.A. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 2005, 6(8):611-622.
3. Ahmed S., Passos J.F., Birket M.J., et al. Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress. J Cell Sci 2008, 121(Pt 7):1046-1053.
4. Haendeler J., Drose S., Buchner N., et al. Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial dna and function from damage. Arterioscler Thromb Vasc Biol 2009, 29(6):929-935.
5. Park J.I., Venteicher A.S., Hong J.Y., et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009, 460(7251):66-72.
6. Epel E.S., Blackburn E.H., Lin J., et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U. S. S A 2004, 101(49):17312-17315.
7. Valdes A.M., Andrew T., Gardner J.P., et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005, 366(9486):662-664.
8. Samani N.J., Boultby R., Butler R., et al. Telomere shortening in atherosclerosis. Lancet 2001, 358(9280):472-473.
9. Farzaneh-Far R., Cawthon R.M., Na B., et al. Prognostic value of leukocyte telomere length in patients with stable coronary artery disease: data from the Heart and Soul Study. Arterioscler Thromb Vasc Biol 2008, 28(7):1379-1384.
10. Brouilette S., Singh R.K., Thompson J.R., et al. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol 2003, 23(5):842-846.
11. van der Harst P., van der Steege G., de Boer R.A., et al. Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol 2007, 49(13):1459-1464.
12. Brouilette S.W., Moore J.S., McMahon A.D., et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007, 369(9556):107-114.
13. Carnevale R., Pignatelli P., Di Santo S., et al. Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients. Atherosclerosis 2010, 213(1):225-234.
14. Kumar V.L., Guruprasad B., Wahane V.D. Atorvastatin exhibits anti-inflammatory and anti-oxidant properties in adjuvant-induced monoarthritis. Inflammopharmacology 2010, 18(6):303-308.
15. Lundberg S., Lundahl J., Gunnarsson I., et al. Atorvastatin-induced modulation of monocyte respiratory burst in vivo in patients with IgA nephropathy: a chronic inflammatory kidney disease. Clin Nephrol 2010, 73(3):221-228.
16. Maack C., Kartes T., Kilter H., et al. Oxygen free radical release in human failing myocardium is associated with increased activity of Rac1-GTPase and represents a target for statin treatment. Circulation 2003, 108(13):1567-1574.
17. Murrow J.R., Sher S., Ali S., et al. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. J Clin Lipidol 2012, 6(1):42-49.
18. Sathyapalan T., Shepherd J., Coady A.M., et al. Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2012, 97(11):3951-3955.
19. Spyridopoulos I., Hoffmann J., Aicher A., et al. Accelerated telomere shortening in leukocyte subpopulations of patients with coronary heart disease: role of cytomegalovirus seropositivity. Circulation 2009, 120(14):1364-1372.
20. Taleb S., Tedgui A., Mallat Z. Adaptive T cell immune responses and atherogenesis. Curr Opin Pharmacol 2010, 10(2):197-202.
21. Rossmann A., Henderson B., Heidecker B., et al. T-cells from advanced atherosclerotic lesions recognize hHSP60 and have a restricted T-cell receptor repertoire. Exp Gerontol 2008, 43(3):229-237.
22. Zhou X., Stemme S., Hansson G.K. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol 1996, 149(2):359-366.
23. Zhou X., Robertson A.K., Rudling M., et al. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res 2005, 96(4):427-434.
24. Blank N., Schiller M., Krienke S., et al. Atorvastatin inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis. J Immunol 2007, 179(6):3613-3621.
25. Dunn S.E., Youssef S., Goldstein M.J., et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006, 203(2):401-412.
26. Radulovic L.L., Cilla D.D., Posvar E.L., et al. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 1995, 35(10):990-994.
27. Dimmeler S., Aicher A., Vasa M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001, 108(3):391-397.
28. Spyridopoulos I., Haendeler J., Urbich C., et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 2004, 110(19):3136-3142.
29. Saliques S., Teyssier J.R., Vergely C., et al. Circulating leukocyte telomere length and oxidative stress: a new target for statin therapy. Atherosclerosis 2011, 219(2):753-760.
30. Boccardi V., Barbieri M., Rizzo M.R., et al. A new pleiotropic effect of statins in elderly: modulation of telomerase activity. FASEB J 2013, 27(9):3879-3885.
31. Chiang Y.J., Hemann M.T., Hathcock K.S., et al. Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol 2004, 24(16):7024-7031.
32. Blasco M.A., Lee H.W., Hande M.P., et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997, 91(1):25-34.
33. Breault D.T., Min I.M., Carlone D.L., et al. Generation of mTert-GFP mice as a model to identify and study tissue progenitor cells. Proc Natl Acad Sci U S A 2008, 105(30):10420-10425.
34. Montgomery R.K., Carlone D.L., Richmond C.A., et al. Mouse telomerase reverse transcriptase (mTert) expression marks slowly cycling intestinal stem cells. Proc Natl Acad Sci U S A 2011, 108(1):179-184.
35. Baerlocher G.M., Vulto I., de Jong G., et al. Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc 2006, 1(5):2365-2376.
36. Spyridopoulos I., Erben Y., Brummendorf T.H., et al. Telomere gap between granulocytes and lymphocytes is a determinant for hematopoetic progenitor cell impairment in patients with previous myocardial infarction. Arterioscler Thromb Vasc Biol 2008, 28(5):968-974.
37. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359(21):2195-2207.
38. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376(9753):1670-1681.
39. Sinensky M., Beck L.A., Leonard S., et al. Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 1990, 265(32):19937-19941.
40. Cho K.J., Hill M.M., Chigurupati S., et al. Therapeutic levels of the HMG-CoA reductase inhibitor lovastatin activate Ras signaling via phospholipase D2. Mol Cell Biol 2011, 31(6):1110-1120.
41. Henson S.M., Franzese O., Macaulay R., et al. KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. Blood 2009, 113(26):6619-6628.
42. de Jesus B.B., Schneeberger K., Vera E., et al. The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell 2011, 10(4):604-621.
43. Harley C.B., Liu W., Blasco M., et al. A natural product telomerase activator as part of a health maintenance program. Rejuvenation Res 2011, 14(1):45-56.